Intelisci’s Post

An insightful article by Labiotech.eu on the challenging journey to funding a biotech venture. It's not just about securing funds but also the value investors can bring. The right mix of dilutive and non-dilutive funding sources is crucial, involving governmental grants, subsidies, VC investments, Corporate VC investments, partnerships, collaborations, and the IPO. The latter is not discussed in this article. Hope to see more on that soon. It's time! 👍👊 #Biotech #Lifesciences #Ecosystembuilding #Startup #ScaleUp #Growth #Funding

A common mistake biotech startups make in their funding strategy is not having a clear path mapped out for commercialization. The journey to funding a #startup in the #biotech industry is long and it is not only about the funds but also about the added value investors can bring to your company. The adequate combination of sources vastly depends on your business model but governmental grants and subsidies in addition to VC investments seem to be the way to go in the industry as companies are dealing with long timelines and are rarely able to generate revenue early on.

How to navigate the biotech funding landscape? 🚣 Funding a startup is challenging, and it can be even trickier in the biotech industry. While it seems that biotech funding is in recovery, venture capital (VC) investment is still cautious and tends to go for de-risk opportunities. 💸 It is a good thing that’s not the only option for startups! While VC remains essential startups need to rely on multiple sources throughout their journey: grants, corporate venture capital, partnerships, debt financing…  We reached out to experts to see clearer in this sometimes opaque environment. 🧭 Find out what they told us in our latest article! ⬇️ https://lnkd.in/dtWt6vTH #biotechfunding #startupchallenges #venturecapital #biotechstartups #grants #partnerships #biotechindustry #healthcareinnovation #startupfunding Kathleen Lee | Greater Phoenix Economic Council | Jörg Klumbis | Peptomyc | Katerina Stroponiati | Brilliant Minds | Michael Salako PhD MBA | Start Codon | Abveris | AngelList | Life Science Angels | TCA Venture Group

💡 Very insightful article on securing the right mix of funding sources for #biotech startups. 🚀 "The journey to funding a startup in the biotech industry is long and it is not only about the funds but also about the added value investors can bring to your company. The adequate combination of sources vastly depends on your business model but governmental grants and subsidies in addition to VC investments seem to be the way to go in the industry as companies are dealing with long timelines and are rarely able to generate revenue early on."

Great article about biotech startup funding, including The Complex Funding Landscape & The Role of Strategic Funding Choices: Be very careful in selecting who to be your investor & partner 👍 #Biotech #StartupFunding #Entrepreneurship #crowdfunding #venturecapital #angelinvestor #DigitalTransformation #health

Venture capital funding is becoming harder to secure for startup companies. But still, plenty of Triangle companies scored big in the past year. #venturecapital #funding #startups #investors #investing #raleigh #durham #northcarolina

The Italian Tech Alliance's #VentureAcademy concludes its training programme today. Three months of engaging theoretical and practical lessons on the functioning of venture capital and innovative companies, given by experts in venture capital and start-up. #venturecapital #biotech #startup #entrepreneur #investors #startuplife #startupfunding #vc #vcfunding

Biotech startups face unique challenges in the funding landscape, requiring significant initial capital to fuel R&D, clinical trials, and regulatory approvals before seeing any revenue. This high-risk, high-reward environment can be daunting to navigate. The latest article by Labiotech.eu provides a comprehensive guide to the various funding options available to biotech startups. #Biotech #Startups #Funding #RD #Innovation

Meet the next Venture Partner of ATIF - Avik Arakelian, CFA !🌎 Avik Arakelian is a biotech venture investor with over 10 years of experience managing investments spanning from startup creation stages to IPOs and M&As. Our interview: 1. Why did you join ATIF? We live at a very unique moment in terms of global technological transformations, especially with the integration of AI into our lives, from everyday apps to complex fields like computational biology. Armenia, while being a small country with a challenging history, is facing both difficulties and opportunities in this era. The emergence of new technologies are reducing the impact of geographical and physical boundaries, opening up new possibilities for the country's growth. The key to progress lies in creating an ecosystem that nurtures innovation. I am inspired by the vision of ATIF, a project initiated by my close friends, and joined as a venture advisor to support the fund in making a positive impact. 2. What are the areas of your interest and why? I have been managing venture funds primarily focused on biotech. While my interests extend to space tech and cybersecurity, among others, I am passionate about how new technologies can extend healthy human lifespans. Unfortunately, Armenia ranks below 50th in global healthy life expectancy and even below 60th in total life expectancy. Although this is not the worst case, significant healthcare issues in Armenia could be addressed by novel technologies, from AI-powered early diagnostics of widespread chronic diseases to new targeted therapies. We are actually the first generation to understand why we age at a biological level, and with advances in AI, we finally have the technologies that can address the complexities of human biology. We need platforms to bring these technologies to Armenia. And ATIF should be one of them. 3. What is your vision of the fund at the moment? There are several unique aspects of ATIF that significantly drove my interest in the project. It offers a very unique venture model, which is rare to find elsewhere. First, investors in the ATIF are amazing individuals from all around the world, and they all will be involved in active roles in the fund, unlike in traditional VC funds. Second, the fund is structured under the local regulations of Armenia, providing a direct route to improving the regulatory framework, essential for attracting more investors to our country. This gives us the opportunity to advance in terms of the investment climate and enhance the country’s reputation in the global venture market. I envision seeing more companies from around the world, featuring an Armenian fund as their investor. My vision is for ATIF to become a unique platform for interaction, collaboration, and joint projects, not only for Armenians worldwide but also for global institutions and corporations interested in Armenia as a growing and advancing nation. #ATIF #armtechimpactvc #armtechventures #armenia #startupsarmenia

Venture capital fundraising in Israel plummeted significantly in 2023 from the year before, according to the latest annual report by IVC–Gornitzky–KPMG Israel in association with the Israel Innovation Authority רשות החדשנות. The report, which explores investment trends in the Israeli tech ecosystem, found that in 2023 – a fraught year of protests over planned judicial reforms, the worst terror attack in the country’s history and three months of war – just 21 Israeli VC funds managed to raise $1.52 billion. The figures mark a drop of 74 percent in funds raised compared to 2022 (the lowest since 2015) and a 66-percent decrease in the number of funds. “Following the report’s findings and the market’s negative trends in 2023, the Innovation Authority implemented strategic initiatives to boost available capital,” said Dror Bin, CEO of Israel Innovation Authority. #israelinnovation #israelitech #startupnation #hitech #startups #venturecapital #fundraising #investments | IVC Data and Insights |